Charles Davant, MD
Family Medicine · Blowing Rock, NCNPI 1396709176
Payments from drug & device makers
Across 357 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$844
- GSK$762
- Lilly USA, LLC$641
- AbbVie$539
- Johnson & Johnson$443
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,471100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $1,096 |
| Novo Nordisk | 59 | $844 |
| GSK | 33 | $762 |
| Lilly USA, LLC | 38 | $641 |
| AbbVie(2 entities) | 37 | $539 |
| Johnson & Johnson | 30 | $443 |
| Pfizer | 27 | $363 |
| Novartis | 12 | $217 |
| Amgen | 9 | $207 |
| Lundbeck LLC | 7 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $163 |
| Phathom Pharmaceuticals, Inc. | 2 | $139 |
| Dexcom, Inc. | 3 | $126 |
| Merck | 8 | $120 |
| Astellas Pharma US Inc | 4 | $95 |
| Zealand Pharma US, Inc. | 1 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Mylan Specialty L.p. | 3 | $44 |
| Verona Pharma, Inc. | 2 | $40 |
| Corium, LLC | 2 | $36 |
| Tris Pharma Inc | 2 | $36 |
| Viatris Specialty LLC | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Bayer | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Tolmar, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$141
- XARELTO$125
- Wegovy$125
- BREZTRI$125
- VOQUEZNA$118
How this compares
$6,485 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 108 | $119,621 |
| FarxigaDapagliflozin Propanediol | 62 | $69,424 |
| OzempicSemaglutide | 43 | $51,741 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $32,078 |
| MounjaroTirzepatide | 29 | $27,493 |
| JanuviaSitagliptin Phosphate | 33 | $25,588 |
| RybelsusSemaglutide | 20 | $21,909 |
| JardianceEmpagliflozin | 17 | $19,435 |
| TrintellixVortioxetine Hydrobromide | 11 | $15,254 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $11,457 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,338 |
| OxycontinOxycodone Hcl | 13 | $7,838 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,603 |
| Fentanyl | 34 | $4,236 |
| LivaloPitavastatin Calcium | 11 | $3,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $363 | $119,621108 claims |
| AstraZenecaFarxiga, Symbicort | $1,096 | $80,881105 claims |
| Novo NordiskOzempic, Rybelsus | $844 | $73,65063 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $762 | $41,41652 claims |
| Lilly USA, LLCMounjaro | $641 | $27,49329 claims |
| MerckJanuvia | $120 | $25,58833 claims |
| Boehringer IngelheimJardiance | $13 | $19,43517 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $163 | $15,25411 claims |
| AbbVieSynthroid | $539 | $2,10716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Blowing Rock
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.